MD Anderson Cancer Center: KRAS Inhibitor Sotorasib Appears Safe, Achieves Durable Clinical Benefit in Early Trial
September 21, 2020
September 21, 2020
HOUSTON, Texas, Sept. 21 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 20:
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits. Results from the trial were published today in the New England Journal of Medicine and data from the lung cancer cohort also were presente . . .
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits. Results from the trial were published today in the New England Journal of Medicine and data from the lung cancer cohort also were presente . . .